Cue Biopharma, Inc.
$0.85
▼
-11.2%
2026-04-21 06:18:00
www.cuebiopharma.com
NCM: CUE
Explore Cue Biopharma, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$82.97 M
Current Price
$0.85
52W High / Low
$1.03 / $0.17
Stock P/E
—
Book Value
$0.27
Dividend Yield
—
ROCE
-92.35%
ROE
-121.11%
Face Value
—
EPS
$-0.28
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
—
Beta
—
Debt / Equity
0.16
Current Ratio
2.74
Quick Ratio
2.74
Forward P/E
-1.05
Price / Sales
—
Enterprise Value
—
EV / EBITDA
—
EV / Revenue
—
Rating
—
Target Price
—
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Solid Biosciences Inc. | $8.49 | — | $835.34 M | — | -90.02% | -1.1% | $8.87 / $2.41 | $2.28 |
| 2. | Monte Rosa Therapeutics, Inc. | $19.81 | — | $1.58 B | — | -14.1% | -16.94% | $25.77 / $3.51 | $3.56 |
| 3. | Gossamer Bio, Inc. | $0.42 | — | $98.57 M | — | -150.03% | 365.33% | $3.87 / $0.32 | $-0.53 |
| 4. | Armata Pharmaceuticals, Inc. | $12.5 | — | $421.28 M | — | -45.96% | 130.37% | $16.34 / $1.11 | $-6 |
| 5. | Palatin Technologies, Inc. | $22.07 | — | $39.22 M | — | 478.76% | -3.79% | $31 / $2 | $6.53 |
| 6. | BeyondSpring Inc. | $1.78 | — | $73 M | — | -72.39% | 3.09% | $3.44 / $1.21 | $-0.8 |
| 7. | Opus Genetics, Inc. | $5.54 | — | $394.17 M | — | -90.9% | -2.42% | $5.81 / $0.71 | $0.22 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 21.94 M | 2.15 M | 2.95 M | 0.42 M | 1.58 M | — |
| Operating Profit | 1.96 M | -7.54 M | -8.63 M | -12.3 M | -9.63 M | — |
| Net Profit | 1.58 M | -7.45 M | -8.48 M | -12.26 M | -9.5 M | — |
| EPS in Rs | 0.02 | -0.08 | -0.09 | -0.13 | -0.1 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 27.47 M | 9.29 M | 5.49 M | 1.25 M |
| Operating Profit | -26.52 M | -41.59 M | -51.99 M | -53.5 M |
| Net Profit | -26.6 M | -40.67 M | -50.73 M | -53.01 M |
| EPS in Rs | -0.27 | -0.42 | -0.52 | -0.54 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 42.21 M | 32.19 M | 61.53 M | 91.28 M |
| Total Liabilities | 15.78 M | 14.69 M | 24.45 M | 25.6 M |
| Equity | 26.43 M | 17.5 M | 37.09 M | 65.68 M |
| Current Assets | 36.98 M | 25.14 M | 51.45 M | 77.19 M |
| Current Liabilities | 13.49 M | 13.69 M | 17.08 M | 11.55 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -21.69 M | -36.33 M | -39.96 M | -41.81 M |
| Investing CF | 0.07 M | 0.03 M | 25 M | -24.61 M |
| Financing CF | 26.29 M | 10.24 M | 11.86 M | 53.66 M |
| Free CF | -21.86 M | -36.4 M | -39.96 M | -41.98 M |
| Capex | -0.18 M | -0.07 M | — | -0.17 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 69.16% | 340.96% | — | — |
| Earnings Growth % | 19.83% | 4.3% | — | — |
| Profit Margin % | -437.97% | -924.1% | -4257.83% | — |
| Operating Margin % | -447.86% | -947.03% | -4297.35% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -404.09% | -838.83% | -4055.5% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.